Note:

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between
this translated document and the Japanese original, the original shall prevail.

Summary of Consolidated Financial Results for the Third Quarter of Fiscal Year 2022 Ending March 31, 2023
<Under Japanese GAAP>
January 31, 2023

Company Name:
Stock Listings:
Code Number:
URL:
Representative Director:
Inquiries:

SEKISUI KASEI CO., LTD.
Tokyo Stock Exchange4228
https://www.sekisuikasei.com
Mr. Masato Kashiwabara, President
Mr. Katsumi Sasaki, Senior Managing Executive Officer
Head of Corporate Strategic Headquarters+81-3- 3347-9618
February 14, 2023
No
No

TEL:
Scheduled date for submission of quarterly financial statement:
Quarterly earnings supplementary explanatory documents:
Quarterly earnings results briefing:(Figures rounded down to the nearest million yen)
1. Consolidated Business Results for the Third Quarter (April 1, 2022 to December 31, 2022)(1) Consolidated Business Results(% figures represent changes from the same period of the previous year.)
Net Income
Net Sales
Operating Income
Ordinary Income
Attributable to
Owners of Parent
Millions of yen%

Millions of yen%

Millions of yen%

Millions of yen%

FY 2022 (First 9 months)
93,0895.4
161(74.7)
239(67.1)(245)
FY 2021 (First 9 months)
88,345637(45.5)
728(32.6)(6,150)Note. Comprehensive Income: FY2022 (First 9 months): 1,350 million yen [ - %] FY2021 (First 9 months): (7,525) million yen [ - %]Net Income
Attributable to
Owners of Parent
per Share

Net Income
Attributable to
Owners of Parent
per Share (Diluted)
yenyen
FY 2022 (First 9 months)(5.43)FY 2021 (First 9 months)(136.15)
Note. The Company have applied the “Accounting Standard for Revenue Recognition” (ASBJ Statement No.29, March 31, 2020) and related
implementation guidance from the beginning of the first quarter of the previous fiscal year. The percentage change in net sales for thenine months ended December 31, 2021, which were affected by this change, in not shown.
(2) Consolidated Financial Position
Total Assets
Net Assets
Equity to Total Assets
Millions of yen
Millions of yen%
As of December 31, 2022
152,672
59,171
38.3
As of March 31, 2022
143,308
58,242
40.1
Reference: Equity: As of December 31,2022: 58,426 million yen As of March 31 2022: 57,525 million yen
Equity: Shareholders’ Equity including Accumulated Other Comprehensive Income
2. Dividend Status
Dividend per Share
(Date of Record)Year-end

Full year

At the end of 1st Q

At the end of 2nd Q

At the end of 3rd Q

yen
-

yen
5.00
3.00

yen
-

yen
7.00

yen
12.00

-

9.00

12.00

FY 2021
FY 2022
FY 2022 (outlook)
Note. Recent revision of dividend estimates: No

3. Consolidated Outlook for FY2022 (April 1, 2022 to March 31, 2023)(% figures represent changes from the same period of the previous year.)
Net Sales

Operating Income

Millions of yen%
Millions of yen%
Full Year125,000
6.3
950(35.1)
Note. Recent revision of consolidated earnings estimates: No

Ordinary Income
Millions of yen

1,080

%
(23.0)Net Income
Attributable to
Owners of
Parent per ShareNet Income
Attributable to
Owners of Parent
Millions of yen

100

%
-

yen
2.21

SEKISUI KASEI CO., LTD. (4228) Consolidated Financial Results for the Third Quarter of Fiscal Year 2022 Ended March 31, 2023

Note:(1) Significant change of subsidiary companies during the term
(Change of specified subsidiaries that affected the scope of consolidated reporting): No(2) Application of special methods for quarterly consolidated financial statements: No(3) Changes to the accounting policy, changes or restatements of the accounting estimatesa) Changes caused by revisions to accounting principles: Nob) Changes other than a) : Noc) Amendments to accounting estimates : Nod) Restatements : No
(4) Number of shares outstanding (common stock)a) Number of shares outstanding at the end of term (including treasury shares):
As of December 31, 2022
46,988,109 shares
As of March 31, 2022
46,988,109 sharesb) Treasury shares at the end of term:
As of December 31, 2022
1,712,925 shares
As of March 31, 2022
1,794,266 sharesc) Average outstanding shares in the period (quarterly consolidated cumulative total):
As of December 31, 2022
45,242,697 shares
3rd Q of FY2021
45,171,170 shares

Note: Execution chart for audit procedures
The financial Instruments and Exchange Law does not require this brief announcement of the most recent financial statements to be
subject to audit review.
Note: Remarks on appropriate use of forecasted resulted of operation and other special matters(Cautionary statement regarding forward-looking statements)
The earnings forecasts and other forward-looking statement presented in this report are based on information available at the time of its
issue and on certain assumption that the Group considers reasonable. Forward-looking statements in no capacity represent a guaranteethat the Group will achieve the stated amounts. Various factors can cause actual results to differ materially from the forecasts. For
important matters regarding the conditions associated with the assumptions of these forecasts and their appropriate use, please see “1.
Qualitative Information on Quarterly Financial Results, (3) Explanation of Consolidated Financial Results Forecasts and Other Forwardlooking Information” on page 3.

Table of Contents
1. Qualitative Information on Quarterly Financial Results ........................................................................................... 2(1) Explanation of Operating Results......................................................................................................................... 2(2) Explanation of Financial Position ........................................................................................................................ 3(3) Explanation of Consolidated Financial Results Forecasts and Other Forward-looking Information ................... 4
2. Quarterly Consolidated Financial Statements and Principal Notes .......................................................................... 5(1) Quarterly Consolidated Balance Sheets ............................................................................................................... 5(2) Quarterly Consolidated Statements of Income and Comprehensive Income ....................................................... 7
Quarterly Consolidated Statements of Income
First 9 months, Fiscal Year 2022 ........................................................................................................................ 7
Quarterly Consolidated Statements of Comprehensive Income
First 9 months, Fiscal Year 2022 ........................................................................................................................ 8(3) Quarterly Consolidated Statements of Cash Flows .............................................................................................. 9(4) Notes to Quarterly Consolidated Financial Statements ...................................................................................... 10(Notes on going concern assumption) ................................................................................................................ 10(Notes in case of significant changes in shareholders’ equity) ........................................................................... 10(Segment information, etc.) ................................................................................................................................ 11-1-

1. Qualitative Information on Quarterly Financial Results(1) Explanation of Operating Results
During the nine months ended December 31, 2022, countries around the world relaxed restrictions on behavior imposed
as a result of novel coronavirus infectious disease (COVID-19) while taking measures to prevent infection, which led
to signs of a resumption in economic activity centered on personal consumption, but the prolongation of the situationin Ukraine and continued inflationary pressure caused by soaring energy prices and logistics costs led to continued
uncertainty for the global economy. In the automotive industry, shortages of semiconductors and disruption to supply
chains across the world has continued to affect production activities. In the area of electronics, there has been a softeningof demand for personal computers and other products, and LCD panel manufacturers continue to apply inventory
corrections. Although the Japanese economy is showing signs of recovery toward a normalization of socio-economic
activities despite having been hit by an 8th wave of COVID-19, uncertainty continues to linger due to concerns about
falling consumption caused by soaring energy and other prices, and volatility in the foreign exchange and interest rate
markets. In addition, responses to environmental issues, such as reductions in greenhouse gas emissions and the
problem of climate change, are becoming increasingly important.
In Japan’s foam plastics industry, food container-related demand, primarily for home meals and home-meal
replacements, is slowing due in part to the easing of restrictions on behavior. Due to the impact of the continued shortageof semiconductors and logistics disruption, demand for parts, transport materials and packaging materials has yet toexperience a full-fledged recovery, and high prices for energy and other factors remain an issue.
Against this challenging business environment, the Group is working to establish a resilient earnings base based on
ESG management in order to contribute to a sustainable society and achieve a sustainable enhancement of its corporate
value, as stated in the basic policy of the three-year mid-term management plan, “Spiral-up 2024,” which was launchedthis fiscal year. At the same time, the safety and health of our business partners and the Group’s employees are our firstpriority, and we are taking measures to avoid risks related to COVID-19 to the maximum extent possible. We havepositioned “strengthening the earnings structure” as a key issue of the plan, and are working to restructure our businessportfolio through selection and concentration of management resources, make drastic innovations in production andrapidly generate profits from developed products. In order to promote a shift to businesses that solve environmental
and social issues, we have also positioned “expanding Sustainable Star Products through recycling-based business” and“striving to achieve carbon neutrality” as key issues, while further striving to strengthen the promotion of SKG-5R*
activities. As part of this initiative, we have developed RETONA FOAM BIO, a foam derived from biodegradable
plastic, and have begun proposing it for use in environmentally sensitive display applications. Going forward, we willcontinue to work on expanding the BIOCellular* brand product lineup. Moreover, in order to strengthen the
management foundation in these highly uncertain times, as well as further nurturing the Group corporate culture of
Zen-in Keiei, we have clarified the corporate philosophy and formulated “Target 2030” as an objective for 2030, which
was announced in January 2023. Going forward, we will further strengthen initiatives aimed at putting this into practice.
In terms of profits, we responded to multiple negative impacts in the first half, such as those of the global supply chain
disruption resulting from lockdowns in Shanghai, China and other locations, the fire at Sekisui Kasei Oita Co., Ltd.,and soaring prices for raw materials and fuel, by steadfastly working to pass higher inputs on to selling prices, reduce
costs and cut fixed expenses, but we were unable to completely offset these negative factors.
As a result, for the nine months ended December 31, 2022, the Company posted net sales of ¥93,089 million (up 5.4%
year on year), operating income of ¥161 million was recorded (down 74.7% year on year), ordinary income of ¥239
million (down 67.1% year on year). After recording extraordinary income of ¥794 million derived from partial sales ofinvestment securities, and making adjustments to income taxes, this resulted in a net loss attributable to owners of theparent of ¥245 million (compared to a net loss of ¥6,150 million for the same period the previous fiscal year).
* “SKG-5R” refers to SKG as SEKISUI KASEI Group, and 5R as Reduce, Reuse, Recycle, Replace, and Re-create.
BIOCellular is the Company’s brand for the category of products that use biodegradable plastics or plastics derived
from biomass.
The results for each segment are as follows.
We have defined food and housing/energy in the Human Life segment, and mobility, electronics, and medical/healthcare-2-

in the Industry segment, as key issue fields. We will work to restructure our business portfolio with the aim of“strengthening the earnings structure,” as stated in the mid-term plan.
<Human Life segment>
Net sales in the Human Life segment reached ¥39,630 million (up 5.3% year on year), with a segment profit of ¥1,872
million (down 28.4% year on year).
Shipments in the Food field were down overall year on year. Although flows of people are returning and driving signsof a recovery in takeout containers, as well as in lunchboxes and other products related to tourist and restaurant demand,
food container demand related to home meals and home-meal replacements is on a downward trend. In agricultural
applications, shipments rose year on year, but fishery remained weak due to the trend towards declining catches.
In the Housing/Energy field, civil engineering was weak due to delays in the progress of construction projects, butconstruction materials performed strongly.
Although demand related to take-out containers remained strong, there were signs of a slowdown in fresh food trays
used in supermarkets and elsewhere, which together with a fall in instant noodle-related demand resulted in a year-onyear decline in sales volume of ESLEN Sheets (foamed polystyrene sheets), our mainstay product. Sales volume of
ESLEN Beads (expandable polystyrene beads) recorded a year-on-year decline overall, with beads for cushions andother life goods showing a slowing of the demand growth of the previous year, and weakness being seen in fisheryrelated demand.
In response to repeated sharp increases in the price of raw materials and secondary resources as well as cost of energy,
we worked to reduce costs and fixed expenses and also passed higher inputs on to selling prices. However, delays inaddressing soaring prices during the first half, costs incurred as a result of transferring products from other factories
following the fire at Sekisui Kasei Oita in April, and other factors put pressure on margins, and profits declined.
<Industry segment>
Net sales in the Industry segment reached ¥53,458 million (up 5.4% year on year), with a segment loss of ¥750 million,
compared to a loss of ¥1,610 million for the same quarter of the previous fiscal year.
In the Mobility field, demand for automotive parts applications was sluggish in the first half due to the impact ofautomaker production cutbacks implemented in response to shortages of semiconductors and other parts in countries
around the world, and to lockdowns in various parts of China. We saw a trend toward recovery in some regions in thethird quarter, however, and sales for PIOCELAN (polystyrene/polyolefin hybrid resin foam), the use of which in parts
packaging applications continues to expand, grew year on year. In Europe, the Proseat Group worked on improvements
such as reductions in fixed costs and consolidation of production, but orders from European automobile manufacturers
continue to stagnate due to shortages of semiconductors and other parts, and as a result of the situation in Ukraine,
while the impact of significant increases in energy costs continued to depress earnings.
In the Electronics field, demand for TECHPOLYMER (organic polymer particles) used in light diffusion applications
for LCD panels, etc. was initially strong, but has remained weak since the second quarter. Due to the impact of the
lockdowns, intensified competition with other materials, and inventory corrections for LCD panels, demand for paneltransport materials and packaging materials using PIOCELAN in China, Taiwan and elsewhere was weak.
In the Medical/Healthcare field, ELASTIL (thermoplastic elastomer foam) performed well due to the expansion ofdemand from midsoles for running shoes to other types of shoe. Sales of ST-gel (functional high-polymer gel) for
applications such as medical electrodes remained strong.
In terms of profits, although we took steps to raise productivity and cut fixed expenses, the time lag between being
affected by the sharp increases in prices for raw materials and fuel and passing them on to customers resulted in a loss.
(2) Explanation of Financial Position
At the end of the third quarter under review, total assets had increased by ¥9,364 million from the end of the previous
year to ¥152,672 million. In assets, increases in notes receivable and accounts receivable resulted in current assets
rising by ¥8,443 million. Non-current assets also increased, by ¥921 million, due mainly to a decrease in the valuation-3-

of investments in securities.
In liabilities, current liabilities rose by ¥3,782 million as a result of increases in notes and accounts payable - trade andother items. In addition, mainly as a result of an increase in long-term loans, long-term liabilities increased by ¥4,653
million. Net assets rose by ¥928 million to ¥59,171 million, due mainly to increases in items such as net unrealized
holding gain on securities. As a result, the equity ratio was 38.3%.
As for cash flows for the nine months ended December 31, 2022, cash flows from operating activities saw proceeds
increase by ¥1,425 million year on year, resulting in ¥396 million in net cash provided by operating activities, due
mainly to the increase in income before income taxes. Due in part to the decline in capital expenditures and to proceedsfrom sales of investments in securities, cash outflows associated with investing activities decreased by ¥1,765 million
year on year, resulting in ¥606 million in net cash used in investing activities. Cash outflows associated with financing
activities decreased by ¥2,168 million year on year, resulting in ¥62 million in net cash used in financing activities, due
mainly to increases in long-term loans. As a result, the balance of cash and cash equivalents as of December 31, 2022
decreased by ¥304 million from the end of the previous fiscal year to ¥10,198 million.
(3) Explanation of Consolidated Financial Results Forecasts and Other Forward-looking Information
Consolidated earnings forecasts for the full year of the fiscal year ending March 31, 2023 are unchanged from theassumptions and figures announced on August 2, 2022.

-4-

2. Quarterly Consolidated Financial Statements and Principal Notes(1) Quarterly Consolidated Balance Sheets(Millions of yen)
As of March 31, 2022
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade, and contract assets
Electronically recorded monetary claims - operating
Merchandise and finished goods
Work in process goods
Raw materials and supplies
Other current assets
Less allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures, net
Machinery, equipment and vehicles, net
Land
Other, net
Total property, plant and equipment
Intangible assets
Other intangible assets
Total intangible assets
Investments and other assets
Investments in securities
Assets for retirement benefits
Other assets
Less allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets-5-

As of December 31, 2022

10,51028,993
6,526
8,633
1,785
4,756
2,617
(52)
63,771

10,20632,981
9,008
9,342
1,660
5,074
3,992
(50)
72,214

15,44813,737
21,413
5,053
55,652

14,90913,056
21,4605,034
54,460

1,131
1,131

1,368
1,368

14,849
6,155
1,796
(47)
22,752
79,536
143,308

16,447
6,310
1,918
(47)
24,62980,457
152,672(Millions of yen)
As of March 31, 2022
Liabilities
Current liabilities
Notes and accounts payable - trade
Electronically recorded obligations - operating
Short-term loans
Accrued income taxes
Provision for bonuses to employees
Provision for bonuses to directors and audit and supervisoryboard members
Provision for loss on business withdrawal of a subsidiary
Other current liabilities
Total current liabilities
Long-term liabilities
Bond
Long-term loans
Liabilities for retirement benefits
Provision for product warranty
Other long-term liabilities
Total long-term liabilities
Total liabilities
Net assets
Shareholders’ equity
Common stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders’ equity
Accumulated other comprehensive income
Net unrealized holding gain on securities
Surplus arising from land revaluation
Translation adjustments
Retirement benefits liability adjustments
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets-6-

As of December 31, 2022

16,065
9,145
16,252767
1,046

20,643
9,344
14,348
476
458

6

49

446
6,985
50,71575
9,100
54,4977,000
13,863
3,608
108
9,769
34,34985,0657,000
17,6353,741
87
10,53939,00393,501

16,533
16,503
16,602(1,448)48,19016,533
16,445
15,904(1,382)47,501

7,442
1,479
745
(332)
9,334
717
58,242
143,308

8,961
1,479
868
(383)
10,924745
59,171
152,672

(2) Quarterly Consolidated Statements of Income and Comprehensive Income
Quarterly Consolidated Statements of Income
First 9 months, Fiscal Year 2022
First 9 months,
FY2021(From April 1,2021
to December 31, 2021)
88,34570,026
18,318
17,681637

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income (loss)
Non-operating income
Interest income
Dividend income
Foreign exchange gains
Subsidy income
Compensation income
Other non-operating income
Total non-operating income
Non-operating expenses
Interest expense
Loss on sales or disposal of equipment
Foreign exchange losses
Other non-operating expenses
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of investments in securities
Total extraordinary income
Extraordinary losses
Impairment losses
Total extraordinary losses
Net income before income taxes
Income taxes
Net income (loss)
Net income attributable to non-controlling interests
Net income (loss) attributable to owners of the parent-7-(Millions of yen)First 9 months,
FY2022(From April 1,2022
to December 31, 2022)
93,08974,93818,15017,989
161

10
328
52
33
290
715

15
349
28
210
130
734

288
125
209
624
728

366
21
112
156
656
239

426
426

794
794

6,271
6,271
(5,116)
1,029(6,145)
4(6,150)

1,033
1,273
(239)
5
(245)

Quarterly Consolidated Statements of Comprehensive Income
First 9 months, Fiscal Year 2022

Net income (loss)
Other comprehensive (loss) income
Net unrealized holding gain on securities
Translation adjustments
Retirement benefits liability adjustments
Total other comprehensive (loss) income
Comprehensive income
Comprehensive income attributable to:
Owners of parent
Non-controlling interests-8-First 9 months,
FY2021(From April 1,2021
to December 31, 2021)(6,145)(Millions of yen)First 9 months,
FY2022(From April 1,2022
to December 31, 2022)(239)(1,757)701(323)(1,379)(7,525)

1,518
122
(50)
1,590
1,350

(7,516)
(9)

1,344
5

(3) Quarterly Consolidated Statements of Cash FlowsFirst 9 months,
FY2021(From April 1,2021
to December 31, 2021)
Cash flows from operating activities
Net income (loss) before income taxes
Depreciation and amortization
Amortization of goodwill
Impairment loss
Increase (decrease) in allowance for doubtful accounts
Interest and dividend income
Interest expense
Decrease in provision for bonuses to employees
Decrease in provision for product warranty
Changes in assets and liabilities for retirement benefits, net
Gain on sales of investments in securities
Loss on sales or disposal of equipment, net
Subsidy income
Increase in notes and accounts receivable
Increase in inventories
Increase in notes and accounts payable
Other, net
SubtotalInterest and dividends received
Interest paid
Proceeds from casualty insurance claims
Proceeds from subsidy income
Income taxes
Net cash used in operating activities
Cash flows from investing activities
Purchases of property, plant and equipment
Proceeds from sales of property, plant and equipment
Purchases of investments in securities
Proceeds from sales of investments in securities
Increase in short-term and long-term loans receivableCollection of short-term and long-term loans receivable
Other, net
Net cash used in investing activities
Cash flows from financing activities
Net increase in short-term loans
Proceeds from long-term loans
Repayment of long-term loans
Dividends paid
Dividends paid to non-controlling shareholders
Other, net
Net cash (used in) provided by financing activities
Effect of exchange rate changes on cash and cash equivalents
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period-9-(Millions of yen)First 9months,
FY2022(From April 1,2022
to December 31, 2022)(5,116)
4,770
128
6,271
8
(338)
288
(589)
(23)
(696)
(426)
123
(33)
(6,138)(1,588)
4,123
(178)
583
338
(304)
156
33
(1,837)(1,028)

1,033
4,209
(3)
(364)
366
(587)
(20)
(123)
(794)
17
(28)
(5,542)
(614)
4,385
(499)
1,433
364
(359)
158
28
(1,228)396(2,955)
32
(3)
531
(7)
14
16
(2,371)(1,936)
69
(3)
1,390
(14)
1
(111)
(606)

4,234
682
(5,405)
(985)
(2)
(754)
(2,231)
101(5,530)12,498
6,968

1,995
8,518
(9,416)
(446)
(1)
(711)
(62)
(31)
(304)
10,503
10,198

(4) Notes to Quarterly Consolidated Financial Statements(Notes on going concern assumption)
Not applicable.
(Notes in case of significant changes in shareholders’ equity)
Not applicable.

- 10 -

(Segment information, etc.)(Segment information)
I. First 9 months of Fiscal Year 2022 (from April 1, 2021 to December 31, 2021)
1. Information on net sales and income (loss) by reportable segment, and information on disaggregation of revenue

Reportable segments
Human Life

Industry

Total

Adjustments(Note 1)

(Millions of yen)Amounts recorded in
the Quarterly
Consolidated
Statements of Income(Note 2)

Net salesJapan
37,517
15,91753,43553,435
Europe22,62522,62522,625Asia
106
10,43010,536
10,536
Other
1
1,746
1,747
1,747
Revenue from contracts with
37,62450,72088,34588,345
customers
Other revenue
Net sales to third parties
37,62450,72088,34588,345Inter-segment net sales or
457
97
555
(555)
transfers
Total
38,08250,81888,900(555)
88,345
Segment income (loss)
2,614(1,610)
1,003
(274)
728
Notes: 1. Adjustments were as follows:
Adjustments for segment income (loss) of ¥ (274) million consisted of inter-segment eliminations of ¥(0) million and companywide expenses not allocated to reportable segments of ¥ (274) million.
2. Segment income (loss) was adjusted for ordinary income in the Quarterly Consolidated Statements of Income.
3. Major products in each segment- Human Life Segment:
ESLEN Beads, ESLEN Sheet, ESLEN Wood, INTERFOAM, other foamed/molded products, ES Dan Mat,ESLEN Block, etc.
- Industry Segment:
PIOCELAN, LIGHTLON, NEOMICROLEN, CELPET, TECHPOLYMER, ST-gel, TECHEATER, ELASTIL,
FOAMAC, ST-LAYER, ST-Eleveat, other foamed/molded products, etc.

2. Information concerning impairment loss on non-current assets or goodwill, etc. for each reportable segment(Significant impairment losses related to non-current assets)
In the Industry segment, the Proseat Group, a consolidated European subsidiary that manufactures and sells automotive parts andmaterials, etc., has been hit by sharp increases in raw material prices and by the impact of reductions in production by automotive
manufacturers affected by semiconductor shortages and other issues. Based on such factors as the trend in the spread of COVID-19
going forward, we have revised our view of the timing of the recovery of the European market, and as a result we have recorded an
impairment loss. The amount of impairment loss recorded, including goodwill, etc., was ¥6,271 million in the third quarter underreview.
(Significant changes in the amount of goodwill)
Due to the Proseat Group in the Industry segment recording an impairment loss for goodwill, the amount of goodwill has decreased.
The decrease in goodwill as a result of this event in the third quarter under review was ¥1,136 million.

- 11 -

II. Third Quarter of Fiscal Year 2022 (from April 1, 2022 to December 31, 2022)
1.Information on net sales and income (loss) by reportable segment, and information on disaggregation of revenue

Reportable segments
Human Life

Industry

Total

Adjustments(Note 1)

(Millions of yen)Amounts recorded in
the Quarterly
Consolidated
Statements of Income(Note 2)

Net salesJapan
39,537
16,71556,25356,253
Europe24,301
24,301
24,301
Asia
93
9,685
9,779
9,779
Other
2,755
2,755
2,755
Revenue from contracts with
39,63053,45893,08993,089customers
Other revenue
Net sales to third parties
39,63053,45893,08993,089Inter-segment net sales or
433
124
557
(557)
transfers
Total
40,06453,58393,647(557)
93,089Segment income (loss)
1,872
(750)
1,121
(881)
239
Notes: 1. Adjustments were as follows:
Adjustments for segment income (loss) of ¥ (881) million consisted of inter-segment eliminations of ¥ (2) million and companywideexpenses not allocated to reportable segments of ¥ (879) million.
2. Segment income (loss) was adjusted for ordinary loss in the Quarterly Consolidated Statements of Income.
3. Major products in each segment- Human Life Segment:
ESLEN Beads, ESLEN Sheet, ESLEN Wood, INTERFOAM, other foamed/molded products, ES Dan Mat,ESLEN Block, etc.
- Industry Segment:
PIOCELAN, LIGHTLON, NEOMICROLEN, CELPET, TECHPOLYMER, ST-gel, TECHEATER, ELASTIL,
FOAMAC, ST-LAYER, ST-Eleveat, other foamed/molded products, etc.

- 12 -